Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
May 11, 2021 16:47 ET
|
Interpace Biosciences, Inc.
● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021...
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
April 19, 2021 07:05 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance...
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
April 12, 2021 07:05 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability...
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
April 05, 2021 16:05 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
February 25, 2021 16:31 ET
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today...
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
February 24, 2021 17:54 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
February 01, 2021 09:27 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
January 28, 2021 09:15 ET
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
November 19, 2020 16:11 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff...